PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
EP1065207A1
(en)
*
|
1999-07-02 |
2001-01-03 |
Aventis Pharma Deutschland GmbH |
Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
|
ES2306671T3
(es)
*
|
1999-10-07 |
2008-11-16 |
Amgen Inc. |
Inhibidores de triazina quinasa.
|
DE19948417A1
(de)
*
|
1999-10-07 |
2001-04-19 |
Morphochem Ag |
Imidazol-Derivate und ihre Verwendung als Arzneimittel
|
JP4078074B2
(ja)
|
1999-12-10 |
2008-04-23 |
ファイザー・プロダクツ・インク |
ピロロ[2,3−d]ピリミジン化合物
|
EP1875900A3
(en)
*
|
2000-01-24 |
2010-07-21 |
Genzyme Corporation |
JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis
|
DE60129926T2
(de)
*
|
2000-01-24 |
2008-06-19 |
Genzyme Corp., Cambridge |
Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
|
MY137020A
(en)
*
|
2000-04-27 |
2008-12-31 |
Abbott Lab |
Diazabicyclic central nervous system active agents
|
HUP0301114A3
(en)
*
|
2000-06-26 |
2004-11-29 |
Pfizer Prod Inc |
Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
US6881737B2
(en)
|
2001-04-11 |
2005-04-19 |
Amgen Inc. |
Substituted triazinyl acrylamide derivatives and methods of use
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
MXPA03011998A
(es)
*
|
2001-06-23 |
2005-07-01 |
Aventis Pharma Inc |
Pirrolopirimidinas como inhibidores de protein cinasa.
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
GT200200234A
(es)
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
US6642381B2
(en)
*
|
2001-12-27 |
2003-11-04 |
Hoffman-La Roche Inc. |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
|
EP1474425B9
(en)
|
2002-01-07 |
2008-07-02 |
Eisai Co., Ltd. |
Deazapurines and uses thereof
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
EP1388541A1
(en)
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
BR0316487A
(pt)
|
2002-11-26 |
2005-10-11 |
Pfizer Prod Inc |
Método todo de tratamento da rejeição de transplantes
|
WO2004093812A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Irm Llc |
Compounds that induce neuronal differentiation in embryonic stem cells
|
US7169918B2
(en)
*
|
2003-10-27 |
2007-01-30 |
Genelabs Technologies, Inc. |
Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
|
WO2005069865A2
(en)
*
|
2004-01-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
GB0403606D0
(en)
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
CA2563699C
(en)
*
|
2004-04-23 |
2014-03-25 |
Exelixis, Inc. |
Kinase modulators and method of use
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006004703A2
(en)
|
2004-06-29 |
2006-01-12 |
Amgen Inc. |
PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
|
CA2575808A1
(en)
|
2004-08-02 |
2006-02-16 |
Osi Pharmaceuticals, Inc. |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
FR2880626B1
(fr)
*
|
2005-01-13 |
2008-04-18 |
Aventis Pharma Sa |
Derives de la purine, compositions les contenant et utilisation
|
US7423043B2
(en)
|
2005-02-18 |
2008-09-09 |
Lexicon Pharmaceuticals, Inc. |
4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
|
EP1891066B1
(en)
|
2005-05-13 |
2010-12-22 |
Irm, Llc |
Compounds and compositions as protein kinase inhibitors
|
JP5071374B2
(ja)
|
2005-07-14 |
2012-11-14 |
アステラス製薬株式会社 |
ヘテロ環ヤヌスキナーゼ3阻害剤
|
EP2251341A1
(en)
|
2005-07-14 |
2010-11-17 |
Astellas Pharma Inc. |
Heterocyclic Janus kinase 3 inhibitors
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
WO2007041130A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Vertex Pharmaceuticals Incorporated |
Deazapurines useful as inhibitors of janus kinases
|
AU2015201850B2
(en)
*
|
2005-12-13 |
2017-03-02 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
MY159449A
(en)
*
|
2005-12-13 |
2017-01-13 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
ATE531718T1
(de)
*
|
2006-03-11 |
2011-11-15 |
Vernalis R&D Ltd |
Als hsp90-inhibitoren verwendete pyrrolopyrimidinderivate
|
KR20090018895A
(ko)
*
|
2006-04-05 |
2009-02-24 |
버텍스 파마슈티칼스 인코포레이티드 |
야누스 키나제의 억제제로서 유용한 데아자푸린
|
EP2043655A2
(en)
|
2006-04-25 |
2009-04-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
GB0608176D0
(en)
*
|
2006-04-25 |
2006-06-07 |
Astex Therapeutics Ltd |
Pharmaceutical Compounds
|
WO2008012635A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
WO2008033745A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
US20080221132A1
(en)
*
|
2006-09-11 |
2008-09-11 |
Xiong Cai |
Multi-Functional Small Molecules as Anti-Proliferative Agents
|
WO2008075007A1
(en)
*
|
2006-12-21 |
2008-06-26 |
Cancer Research Technology Limited |
Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
|
AR064416A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Cancer Rec Tech Ltd |
Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
US20100105661A1
(en)
|
2007-01-12 |
2010-04-29 |
Astellas Pharma Inc. |
Condensed pyridine compound
|
RU2009140319A
(ru)
*
|
2007-04-02 |
2011-05-10 |
Палау Фарма С.А. (Es) |
Производные пирролпиримидина
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
TR201903488T4
(tr)
|
2007-06-13 |
2019-04-22 |
Incyte Holdings Corp |
Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı.
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
GB0713602D0
(en)
*
|
2007-07-12 |
2007-08-22 |
Syngenta Participations Ag |
Chemical compounds
|
AU2008281849B2
(en)
*
|
2007-07-27 |
2013-11-28 |
Janssen Pharmaceutica Nv |
Pyrrolopyrimidines
|
EP2188289B1
(en)
|
2007-08-08 |
2015-10-28 |
Lexicon Pharmaceuticals, Inc. |
(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-piperazines as kinase inhibitors for the treatment of cancer and inflammation
|
WO2009030871A1
(en)
*
|
2007-09-07 |
2009-03-12 |
Vernalis R & D Ltd |
Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
CN101910152B
(zh)
|
2007-11-16 |
2014-08-06 |
因塞特公司 |
作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
|
UA101493C2
(ru)
|
2008-03-11 |
2013-04-10 |
Инсайт Корпорейшн |
Производные азетидина и циклобутана как ингибиторы jak
|
AU2009239500B2
(en)
|
2008-04-21 |
2014-01-30 |
Lexicon Pharmaceuticals, Inc. |
LIMK2 inhibitors, compositions comprising them, and methods of their use
|
WO2009132202A2
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
RS53382B
(en)
|
2008-08-20 |
2014-10-31 |
Zoetis Llc |
PIROL [2,3-D] PIRIMIDINE COMPOUNDS
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
JOP20190230A1
(ar)
|
2009-01-15 |
2017-06-16 |
Incyte Corp |
طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
|
DE102009005193A1
(de)
*
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
WO2010093808A1
(en)
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
AU2010239396B2
(en)
*
|
2009-04-20 |
2016-06-23 |
Auspex Pharmaceuticals, Llc |
Piperidine inhibitors of Janus Kinase 3
|
WO2010135650A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
AR076920A1
(es)
|
2009-05-22 |
2011-07-20 |
Incyte Corp |
3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
|
CN102574857B
(zh)
*
|
2009-07-08 |
2015-06-10 |
利奥制药有限公司 |
作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
|
TWI466885B
(zh)
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
PL2473049T3
(pl)
|
2009-09-04 |
2019-07-31 |
Biogen Ma Inc. |
Inhibitory kinazy tyrozynowej brutona
|
CN102984941B
(zh)
*
|
2009-09-04 |
2016-08-17 |
密执安大学评议会 |
用于治疗白血病的组合物和方法
|
WO2011044481A1
(en)
|
2009-10-09 |
2011-04-14 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
EP2488524B1
(en)
|
2009-10-15 |
2013-07-03 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
US9074143B2
(en)
*
|
2009-12-11 |
2015-07-07 |
Uop Llc |
Process for producing hydrocarbon fuel
|
ES2461967T3
(es)
|
2009-12-18 |
2014-05-21 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
AU2011213198B2
(en)
|
2010-02-05 |
2014-04-24 |
Zoetis Llc |
Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
|
CN102844317B
(zh)
*
|
2010-02-18 |
2015-06-03 |
因西特公司 |
作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
|
PT3050882T
(pt)
|
2010-03-10 |
2018-04-16 |
Incyte Holdings Corp |
Derivados de piperidin-4-ilazetidina como inibidores de jak1
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
EP2590981B1
(en)
*
|
2010-07-09 |
2014-09-03 |
Leo Pharma A/S |
Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
CN102372717B
(zh)
*
|
2010-08-20 |
2014-06-18 |
和记黄埔医药(上海)有限公司 |
吡咯并嘧啶类化合物及其用途
|
WO2012022265A1
(en)
*
|
2010-08-20 |
2012-02-23 |
Hutchison Medipharma Limited |
Pyrrolopyrimidine compounds and uses thereof
|
WO2012022045A1
(en)
*
|
2010-08-20 |
2012-02-23 |
Hutchison Medipharma Limited |
Pyrrolopyrimidine compounds and uses thereof
|
TWI401258B
(zh)
*
|
2010-09-08 |
2013-07-11 |
Hutchison Medipharma Ltd |
吡咯並嘧啶類化合物及其用途
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
US9045485B2
(en)
|
2010-12-16 |
2015-06-02 |
Convergence Pharmaceuticals Limited |
ASK 1 inhibiting pyrrolopyrimidine derivatives
|
WO2012088682A1
(en)
*
|
2010-12-29 |
2012-07-05 |
Shanghai Fochon Pharmaceutical Co Ltd. |
2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
JP2014501772A
(ja)
*
|
2011-01-07 |
2014-01-23 |
レオ ファーマ アクティーゼルスカブ |
タンパク質チロシンキナーゼ阻害薬としての新規スルファミドピペラジン誘導体およびその医薬用途
|
DE102011008352A1
(de)
*
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
JP5813785B2
(ja)
|
2011-02-04 |
2015-11-17 |
デュケイン ユニバーシティー オブ ザ ホリー スピリット |
抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法
|
PT2675451E
(pt)
|
2011-02-18 |
2015-10-16 |
Incyte Corp |
Terapia de combinação com inibidores mtor/jak
|
EP2688890B1
(en)
|
2011-03-22 |
2017-08-30 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
ES2761311T3
(es)
|
2011-04-01 |
2020-05-19 |
Astrazeneca Ab |
Tratamiento terapéutico
|
ES2560611T3
(es)
|
2011-06-20 |
2016-02-22 |
Incyte Holdings Corporation |
Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
|
CA2838738A1
(en)
*
|
2011-06-29 |
2013-01-03 |
Merck Sharp & Dohme Corp. |
Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
|
CA2841111A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Novel pyrrolo pyrimidine derivatives
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
MY175800A
(en)
|
2011-11-30 |
2020-07-09 |
Astrazeneca Ab |
Combination treatment of cancer
|
CA2856722C
(en)
|
2011-11-30 |
2022-11-22 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
EP2788000B1
(en)
*
|
2011-12-06 |
2018-05-30 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
JP6189948B2
(ja)
*
|
2012-06-29 |
2017-08-30 |
ファイザー・インク |
LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン
|
JP6318156B2
(ja)
*
|
2012-09-06 |
2018-04-25 |
プレキシコン インコーポレーテッドPlexxikon Inc. |
キナーゼをモジュレートするための化合物および方法、ならびにその指標
|
WO2014045305A1
(en)
|
2012-09-21 |
2014-03-27 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
CN104662024B
(zh)
*
|
2012-10-26 |
2016-12-07 |
弗·哈夫曼-拉罗切有限公司 |
酪氨酸激酶抑制剂
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
BR112015010663B1
(pt)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
|
TR201902525T4
(tr)
|
2013-02-22 |
2019-03-21 |
Pfizer |
Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu.
|
UA121532C2
(uk)
|
2013-03-06 |
2020-06-10 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки при отриманні інгібітора jak
|
WO2014139388A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
EP3721873A1
(en)
|
2013-08-07 |
2020-10-14 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
KR101930603B1
(ko)
|
2013-12-05 |
2018-12-18 |
화이자 인코포레이티드 |
피롤로[2,3-d]피리미디닐, 피롤로[2,3-b]피라지닐 및 피롤로[2,3-d]피리디닐 아크릴아미드
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
JP6585158B2
(ja)
|
2014-08-12 |
2019-10-02 |
ファイザー・インク |
ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
|
US10246464B2
(en)
|
2014-09-09 |
2019-04-02 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
CN105524067A
(zh)
*
|
2014-09-28 |
2016-04-27 |
江苏柯菲平医药股份有限公司 |
4-取代吡咯并[2,3-d]嘧啶化合物及其用途
|
JP6761815B2
(ja)
|
2015-05-01 |
2020-09-30 |
ファイザー・インク |
ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、ピロロ[2,3−b]ピリジニルアクリルアミド、およびそのエポキシド
|
US10588907B2
(en)
|
2015-06-04 |
2020-03-17 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
MA42544A
(fr)
|
2015-07-31 |
2018-06-06 |
Taiho Pharmaceutical Co Ltd |
COMPOSÉ PYRROLO[2,3-d]PYRIMIDINE OU UN SEL DE CELUI-CI
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
WO2017091681A1
(en)
|
2015-11-24 |
2017-06-01 |
Aclaris Therapeutics, Inc. |
Selective kinase inhibitors
|
CN107098908B
(zh)
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
CN114539284A
(zh)
|
2016-03-16 |
2022-05-27 |
库拉肿瘤学公司 |
经取代的menin-mll抑制剂及使用方法
|
CN107513069A
(zh)
*
|
2016-06-16 |
2017-12-26 |
正大天晴药业集团股份有限公司 |
手性吡咯并嘧啶化合物的制备方法
|
CN107513067A
(zh)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
含有取代环戊基的吡咯并嘧啶化合物
|
WO2018017153A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate forms and compositions of bruton's tyrosine kinase inhibitors
|
US10316038B2
(en)
|
2017-01-25 |
2019-06-11 |
Aclaris Therapeutics, Inc. |
Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
|
RU2761626C2
(ru)
*
|
2017-02-03 |
2021-12-13 |
Лео Фарма А/С |
ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
|
US11944627B2
(en)
|
2017-03-24 |
2024-04-02 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and Ewing's sarcoma
|
CN108794480A
(zh)
*
|
2017-04-28 |
2018-11-13 |
天津药物研究院有限公司 |
吡咯并嘧啶类化合物、其制备方法和用途
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
WO2019060365A1
(en)
|
2017-09-20 |
2019-03-28 |
Kura Oncology, Inc. |
SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
|
SG11202002947TA
(en)
|
2017-11-03 |
2020-04-29 |
Aclaris Therapeutics Inc |
Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
|
US10800775B2
(en)
|
2017-11-03 |
2020-10-13 |
Aclaris Therapeutics, Inc. |
Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
MA52219A
(fr)
|
2018-03-30 |
2021-02-17 |
Incyte Corp |
Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
|
KR20210044822A
(ko)
|
2018-08-10 |
2021-04-23 |
어클라리스 쎄라퓨틱스, 인코포레이티드 |
피롤로피리미딘 itk 억제제
|
GB201818750D0
(en)
*
|
2018-11-16 |
2019-01-02 |
Institute Of Cancer Res Royal Cancer Hospital |
Lox inhibitors
|
CN109394768B
(zh)
*
|
2018-12-10 |
2019-08-23 |
牡丹江医学院 |
一种治疗湿疹的药物及其制备方法
|
CN113993585A
(zh)
*
|
2019-03-27 |
2022-01-28 |
英矽智能科技知识产权有限公司 |
双环jak抑制剂及其用途
|
BR112021021477A2
(pt)
|
2019-05-02 |
2021-12-21 |
Aclaris Therapeutics Inc |
Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
PE20230251A1
(es)
|
2019-11-22 |
2023-02-07 |
Incyte Corp |
Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
BR112022025381A2
(pt)
|
2020-06-11 |
2023-01-24 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes tipo 1
|
WO2023055731A1
(en)
*
|
2021-09-28 |
2023-04-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|